Ulrik Dalgas

Aarhus University
Country flagDenmark

Research Interests

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Background: People with progressive multiple sclerosis (PMS) present motor (eg, walking) and cognitive impairments, and report fatigue. Fatigue encompasses fatigability which is objectively measured by the capacity to sustain a motor or cognitive task. Objective: To investigate the prevalence of walking and cognitive fatigability (CF) and the associated clinical characteristics in a large sample of PMS patients. Methods: PMS patients (25-65 years old) were included from 11 sites (Europe and North America), having cognitive impairment (1.28 standard deviation below normative data for the symbol digit modality test [SDMT]). Walking fatigability (WF) was assessed using the distance walk index (DWI) and CF using the SDMT (scores from the last 30 seconds compared to the first 30 seconds). Additional measures were: cognitive assessment—Brief International Cognitive Assessment for multiple sclerosis (MS), cardiorespiratory fitness, 6-minute walk, physical activity, depressive symptoms, perceived fatigue—Modified Fatigue Impact Scale (MFIS), MS impact—MSIS-29, and walking ability. Results: Of 298 participants, 153 (51%) presented WF (DWI = −28.9 ± 22.1%) and 196 (66%) presented CF (−29.7 ± 15%). Clinical characteristics (EDSS, disease duration, and use of assistive device) were worse in patients with versus without WF. They also presented worse scores on MSIS-29 physical, MFIS total and physical and reduced physical capacity. CF patients scored better in the MSIS-29 physical and MFIS psychosocial, compared to non-CF group. Magnitude of CF and WF were not related. Conclusions: Half of the cognitively-impaired PMS population presented WF which was associated with higher disability, physical functions, and fatigue. There was a high prevalence of CF but without strong associations with clinical, cognitive, and physical functions. Trial Registration Number: The “CogEx-study,” www.clinicaltrial.gov identifier number: NCT03679468.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (17)

Joanne L. Kemp

La Trobe University

AUSTRALIA
View details

Tobias Sejbaek

University of Southern Denmark

DENMARK
View details

Nick Mora Kristensen

Aarhus University

DENMARK
View details

Jenny Freeman

Professor at University of Plymouth

University of Plymouth

UNITED KINGDOM
View details

Troels Kjeldsen

Aarhus University

DENMARK
View details

Søren T. Skou

-

DENMARK
View details

Rachel A Farrell

University College London

UNITED KINGDOM
View details

Frederik Foldager

Aarhus University

DENMARK
View details

Martin Langeskov-Christensen

Aarhus University

DENMARK
View details

Brian M Sandroff

Rutgers University

UNITED STATES
View details

Peter Feys

Hasselt University

BELGIUM
View details

Lisa Urup Tønning

Aarhus University

DENMARK
View details

Maria Pia Amato

University of Florence

ITALY
View details

Helen Dawes

Professor of Clinical Rehabilitation

University of Exeter

UNITED KINGDOM
View details

Luke Connolly

University of Plymouth

UNITED KINGDOM
View details

Lars G Hvid

Aarhus University

DENMARK
View details

John Brincks

Via University College

DENMARK
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.